BRAF and colon carcinoma: The IC50 value for PXL-4720 was approximately 100-fold lower (range: 17.5 to 280 nM) than Sorafenib in melanomas and colon carcinomas that had the BRAFV600E mutation; however, the IC50 value for PLX-4720 was approximately the same as Sorafenib in colon carcinomas and NSCLC without BRAF mutations, but with RAS mutations [10].